Overview

Alternative Non-cross-resistant Adjuvant Chemotherapy for Operable Breast Cancer Non-response to Primary Chemotherapy

Status:
Unknown status

Trial end date:
2019-12-31

Target enrollment:

Participant gender:

Summary

The purpose of this phase Ⅲ, multi-center, prospective, open-label, randomized,controlled study is to determine whether alternative non-cross-resistant adjuvant chemotherapy can increase distant disease free survival(DDFS) in operable patients non-response to primary chemotherapy.

Phase:

Phase 3

Details

Lead Sponsor:

Tao OUYANG

Collaborators:

307 Hospital of PLA
Beijing Chao Yang Hospital
Beijing Municipal Science & Technology Commission
Chinese Academy of Medical Sciences
Peking Union Medical College Hospital
Peking University First Hospital
Peking University People's Hospital

Treatments:

Albumin-Bound Paclitaxel
Paclitaxel